



European Journal of Histochemistry

SUPPLEMENTARY MATERIAL

DOI: [10.4081/ejh.2023.3612](https://doi.org/10.4081/ejh.2023.3612)

**Metformin sensitises osteosarcoma to chemotherapy *via* the IGF-1R/miR-610/FEN1 pathway**

**Suwei Dong,<sup>1,2\*</sup> Yanbin Xiao,<sup>2\*</sup> Ziqiang Zhu,<sup>1\*</sup> Xiang Ma,<sup>2</sup> Zhuohui Peng,<sup>2</sup>  
Jianping Kang,<sup>2</sup> Jianqiang Wang,<sup>1</sup> Yunqing Wang,<sup>1</sup> Zhen Li<sup>3</sup>**

<sup>1</sup>Department of Orthopaedics, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu

<sup>2</sup>Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan

<sup>3</sup>Department of Medical Oncology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

\*These authors contributed equally

**Correspondence:** Zhen Li, Department of Medical Oncology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. E-mail: [lizhenres@163.com](mailto:lizhenres@163.com)

**Key words:** Osteosarcoma; metformin; IGF-1R; FEN1; chemosensitivity.

---

**Note:** The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

### Supplementary Figure 1.

Flow cytometry assessment of metformin and ADM treatment on MG-63 cell apoptosis; \*\*\* $p < 0.001$  vs control.

